Tumor microenvironment-responsive histidine modified-hyaluronic acid-based MnO2 as in vivo MRI contrast agent

Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles

Brain tumors, including primary gliomas and brain metastases, are one of the deadliest tumors because effective macromolecular antitumor drugs cannot easily penetrate the blood-brain barrier (BBB) and blood-brain tumor barrier (BTB). Magnetic nanoparticles (MNPs) are considered the most suitable nanocarriers for the delivery of brain tumor drugs because of their unique properties compared to other nanoparticles. Numerous preclinical and clinical studies have demonstrated the potential of these nanoparticles in magnetic targeting, nuclear magnetic resonance, magnetic thermal therapy, and ultrasonic hyperthermia. To further develop and optimize MNPs for the diagnosis and treatment of brain tumors, we attempt to outline recent advances in the use of MNPs to deliver drugs, with a particular focus on their efficacy in the delivery of anti-brain tumor drugs based on magnetic targeting and low-intensity focused ultrasound, magnetic resonance imaging for surgical real-time guidance, and magnetothermal and ultrasonic hyperthermia therapy. Furthermore, we summarize recent findings on the clinical application of MNPs and the research limitations that need to be addressed in clinical translation.

Novel chitosan/γ-alumina/carbon quantum dot hydrogel nanocarrier for targeted drug delivery

Curcumin (CUR) is among the most natural and effective antitumor drugs for cancer treatment. These drugs have low solubility and short half-lives that reduce their effectiveness in drug release systems. Herein, a hydrogel nanocarrier containing chitosan (CS), alumina (γ-Al2O3), and carbon quantum dots (CQDs) was prepared by the water-in-oil-in-water (W/O/W) double nanoemulsion method. DLS revealed a nanocarrier size of 227 nm, with a zeta potential of -37.8 mV, which corroborates its stability. FE-SEM showed its quasi-spherical shape, FT-IR and XRD confirmed the presence of all the components in the nanocomposite and gave information about the intermolecular interactions between them and the crystalline nature of the nanocarrier, respectively. The drug loading (48 %) and entrapment efficiency (86 %) were higher than those reported previously for other CUR nanocarriers. The drug release profile revealed a controlled and stable release, and a pH-sensitive behavior, with faster CUR release in an acid environment. The breast cancer cell line was examined by cytotoxicity and cell apoptosis analyses. The results showed that the slow release over time and the programmed cell death were due to interactions between CUR and the nanocarrier. Considering the results obtained herein, CS/γAl2O3/CQDs/CUR can be considered as a promising new nanosystem for tumor treatment.

Lyophilized Progenitor Tenocyte Extracts: Sterilizable Cytotherapeutic Derivatives with Antioxidant Properties and Hyaluronan Hydrogel Functionalization Effects

Cultured primary progenitor tenocytes in lyophilized form were previously shown to possess intrinsic antioxidant properties and hyaluronan-based hydrogel viscosity-modulating effects in vitro. The aim of this study was to prepare and functionally characterize several stabilized (lyophilized) cell-free progenitor tenocyte extracts for inclusion in cytotherapy-inspired complex injectable preparations. Fractionation and sterilization methods were included in specific biotechnological manufacturing workflows of such extracts. Comparative and functional-oriented characterizations of the various extracts were performed using several orthogonal descriptive, colorimetric, rheological, mechanical, and proteomic readouts. Specifically, an optimal sugar-based (saccharose/dextran) excipient formula was retained to produce sterilizable cytotherapeutic derivatives with appropriate functions. It was shown that extracts containing soluble cell-derived fractions possessed conserved and significant antioxidant properties (TEAC) compared to the freshly harvested cellular starting materials. Progenitor tenocyte extracts submitted to sub-micron filtration (0.22 µm) and 60Co gamma irradiation terminal sterilization (5−50 kGy) were shown to retain significant antioxidant properties and hyaluronan-based hydrogel viscosity modulating effects. Hydrogel combination products displayed important efficacy-related characteristics (friction modulation, tendon bioadhesivity) with significant (p < 0.05) protective effects of the cellular extracts in oxidative environments. Overall, the present study sets forth robust control methodologies (antioxidant assays, H2O2-challenged rheological setups) for stabilized cell-free progenitor tenocyte extracts. Importantly, it was shown that highly sensitive phases of cytotherapeutic derivative manufacturing process development (purification, terminal sterilization) allowed for the conservation of critical biological extract attributes.